| 000 | 01598 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515203047.0 | ||
| 264 | 0 | _c20100223 | |
| 008 | 201002s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/sj.bjc.6605507 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTrarbach, T | |
| 245 | 0 | 0 |
_aPhase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cFeb 2010 |
||
| 300 |
_a506-12 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptors, TNF-Related Apoptosis-Inducing Ligand _xagonists |
| 700 | 1 | _aMoehler, M | |
| 700 | 1 | _aHeinemann, V | |
| 700 | 1 | _aKöhne, C-H | |
| 700 | 1 | _aPrzyborek, M | |
| 700 | 1 | _aSchulz, C | |
| 700 | 1 | _aSneller, V | |
| 700 | 1 | _aGallant, G | |
| 700 | 1 | _aKanzler, S | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 102 _gno. 3 _gp. 506-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjc.6605507 _zAvailable from publisher's website |
| 999 |
_c19446823 _d19446823 |
||